UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011676
Receipt number R000013653
Scientific Title Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study
Date of disclosure of the study information 2013/09/08
Last modified on 2015/09/07 13:51:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Acronym

Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Scientific Title

Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Scientific Title:Acronym

Esomeprazole 20mg versus rabeprazole 10mg for the resolution of gastroesophageal reflux symptoms, Non-Inferiority randomized open-label cross over comparative study

Region

Japan


Condition

Condition

Gastroesophageal reflux disease

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the resolution of symptoms with esomeprazole 20mg/day or rabeprazole 10mg/day in gastroesophageal reflux disease patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Resolution Rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks

Key secondary outcomes

Improvement rate of gastroesophageal reflux disease symptom with each treatment after 2 weeks


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Esomeprazole20mg/day1,14days

Interventions/Control_2

Rabeprazole10mg/day,14days

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Patients who have freely given written consent to participating in the study after receiving a full explanation (written and oral) of the study.
(2)Patients of either sex who are at least 20 years of age.
(3)Patients whose are taking medication of Proton pump inhibitors or Histamine 2 Receptor Antagonists already can be washout of these medications for one week.

Key exclusion criteria

(1)Patients with a history of gastrointestinal resection or vagotomy
(2)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, bloody disease, cardiac disease or malignant disease.
(3)Women who are pregnant or who may possibly be pregnant, and lactating mothers
(4)Other patients whom the investigator considers unsuitable for admission to the study

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Motoyasu chibai

Organization

Heiwadai clinic

Division name

Surgery

Zip code


Address

4-26-8,Heiwadai,Nerima-ku,Tokyo,Japan

TEL

03-5922-1241

Email

bk2m-cbi@asahi-net.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Motoyasu chibai

Organization

Heiwadai clinic

Division name

Surgery

Zip code


Address

4-26-8,Heiwadai,Nerima-ku,Tokyo,Japan

TEL

03-5922-1241

Homepage URL


Email

bk2m-cbi@asahi-net.or.jp


Sponsor or person

Institute

Heiwadai clinic

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 09 Month 08 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 08 Month 21 Day

Date of IRB


Anticipated trial start date

2013 Year 09 Month 25 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 09 Month 07 Day

Last modified on

2015 Year 09 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013653


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name